Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease

All patients on enzyme replacement therapy could be enrolled in the study. Three medicines are currently available in Russia (Fabagal®, Fabrazyme®, Replagal®) so the patients form three cohorts. For all patients retrospective data are collected for 12 months prior enrollment. All patients are observed prospectively for 6 months. At the point of 6 months patients taking Fabrazyme or Replagal at the moment finish the study. Patients on Fabagal are observed for 12 more months (up to 18 months after enrollment).